1.610USD+2.55%Mkt Cap: 248.34M USDP/E: —Last update: 2026-05-22
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting gr…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap248.34M USD
Enterprise Value129.50M USD
Revenue (TTM)46.88M USD
Gross Profit28.36M USD
Net Income (TTM)168.02M USD
Revenue/Share0.3830 USD
Last Price1.610 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees145
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS19249H1032
Valuation
P/E (Trailing)—
P/E (Forward)-1.37
PEG—
EV/EBITDA-0.79
EV/Revenue2.76
P/S5.17
P/B3.08
EPS (TTM)-1.42
EPS (Forward)-1.15
52W Range
0.710047% of range2.616
52W High2.616 USD
52W Low0.7100 USD
Profitability
Gross Margin67.24%
Oper. Margin-293.67%
EBITDA Margin0.00%
Profit Margin398.43%
ROE275.39%
ROA65.04%
Growth
Revenue Growth62.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF-138.51M USD
CapEx (TTM)—
FCF Margin-57.72%
FCF Yield-10.90%
Net Debt-112.68M USD
Net Debt/EBITDA0.69
Balance Sheet
Debt/Equity0.66
Current Ratio1.56
Quick Ratio1.43
Book Value/Sh0.5100 USD
Cash/Share1.083 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Target (Mean)7.800 USD
Target Range4.000 USD – 12.00 USD
# Analysts5
Ownership
Shares Out.154.25M
Float132.53M
Insiders18.54%
Institutions38.56%
Short Interest
Short Ratio29.3d
Short % Float19.13%
Short % Out.18.56%
Shares Short27.82M
Short (prev mo.)28.14M
Technical
SMA 501.712 (-6.0%)
SMA 2001.564 (+2.9%)
Beta1.02
S&P 52W Chg28.31%
Avg Vol (30d)1.31M
Avg Vol (10d)1.90M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—